Ascorbic Acid Treatment in CMT1A Trial (AATIC)

Inclusion Criteria: * DNA-proven CMT1A patients * Age 12-25 years * CMT 1A patients with symptomatology defined as muscle weakness in at least foot dorsiflexion Exclusion Criteria: Due to possible influence on severity of the neuropathy: * Known other disease that may cause a neuropathy, that may decrease mobility, or that may lead to severe disability or death in a short time * Medication that may cause a neuropathy * Chronic alcohol abuse Due to study medication (ascorbic acid): * Regular use of vitamin C * Clinical or echographic signs of nephrolithiasis * Reduced glomerular filtration rate * Iron overload * No regular dental control at the dentist * Pregnancy or active pregnancy wish for women Due to study design and primary outcome: * Not signing the informed consent * Psychiatric co-morbidity which may influence compliance * Not being comfortable during nerve conduction studies of the median nerve * A too small CMAP amplitude of the abductor pollicis brevis muscle for a proper determination of the nerve conduction velocity of the median nerve